Log in

NASDAQ:DXCMDexCom Stock Price, Forecast & News

$404.23
-35.41 (-8.05 %)
(As of 07/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$402.45
Now: $404.23
$446.50
50-Day Range
$344.85
MA: $393.43
$440.50
52-Week Range
$138.28
Now: $404.23
$446.50
Volume1.55 million shs
Average Volume1.48 million shs
Market Capitalization$37.33 billion
P/E Ratio254.23
Dividend YieldN/A
Beta0.79
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Read More
DexCom logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:DXCM
CUSIP25213110
Phone858-200-0200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.48 billion
Cash Flow$2.20 per share
Book Value$9.64 per share

Profitability

Net Income$101.10 million

Miscellaneous

Employees3,900
Market Cap$37.33 billion
Next Earnings Date7/28/2020 (Confirmed)
OptionableOptionable

Receive DXCM News and Ratings via Email

Sign-up to receive the latest news and ratings for DXCM and its competitors with MarketBeat's FREE daily newsletter.

DexCom (NASDAQ:DXCM) Frequently Asked Questions

How has DexCom's stock been impacted by COVID-19 (Coronavirus)?

DexCom's stock was trading at $252.42 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DXCM stock has increased by 60.1% and is now trading at $404.23. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of DexCom?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 5 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for DexCom.

When is DexCom's next earnings date?

DexCom is scheduled to release its next quarterly earnings announcement on Tuesday, July 28th 2020. View our earnings forecast for DexCom.

How can I listen to DexCom's earnings call?

DexCom will be holding an earnings conference call on Tuesday, July 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) posted its quarterly earnings results on Tuesday, April, 28th. The medical device company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.29. The medical device company earned $405.10 million during the quarter, compared to analyst estimates of $358.34 million. DexCom had a net margin of 9.24% and a return on equity of 26.44%. DexCom's quarterly revenue was up 44.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.05) EPS. View DexCom's earnings history.

What price target have analysts set for DXCM?

21 Wall Street analysts have issued 1-year price objectives for DexCom's shares. Their forecasts range from $190.00 to $500.00. On average, they anticipate DexCom's share price to reach $352.15 in the next twelve months. This suggests that the stock has a possible downside of 12.9%. View analysts' price targets for DexCom.

Has DexCom been receiving favorable news coverage?

News stories about DXCM stock have trended very negative this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. DexCom earned a news impact score of -3.2 on InfoTrie's scale. They also gave media coverage about the medical device company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about DexCom.

Are investors shorting DexCom?

DexCom saw a decline in short interest in June. As of June 30th, there was short interest totaling 4,400,000 shares, a decline of 7.8% from the June 15th total of 4,770,000 shares. Based on an average daily volume of 1,830,000 shares, the days-to-cover ratio is currently 2.4 days. Approximately 4.9% of the company's stock are short sold. View DexCom's Current Options Chain.

Who are some of DexCom's key competitors?

What other stocks do shareholders of DexCom own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), Alibaba Group (BABA), Paypal (PYPL), Netflix (NFLX), Advanced Micro Devices (AMD), salesforce.com (CRM), Vertex Pharmaceuticals (VRTX), Adobe (ADBE), ServiceNow (NOW) and Shopify (SHOP).

Who are DexCom's key executives?

DexCom's management team includes the following people:
  • Mr. Kevin R. Sayer, Exec. Chairman, CEO & Pres (Age 61)
  • Mr. Quentin S. Blackford, Exec. VP & CFO (Age 40)
  • Mr. Steven R. Pacelli, Exec. VP of Strategy & Corp. Devel. (Age 47)
  • Mr. Andrew K. Balo, Exec. VP of Clinical Affairs, Regulatory Strategies & Global Access (Age 71)
  • Mr. Richard B. Doubleday, Exec. VP & Chief Commercial Officer (Age 56)

What is DexCom's stock symbol?

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

Who are DexCom's major shareholders?

DexCom's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.07%), State of Alaska Department of Revenue (0.02%), DNB Asset Management AS (0.01%), IFM Investors Pty Ltd (0.01%), Louisiana State Employees Retirement System (0.00%) and NuWave Investment Management LLC (0.00%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg. View institutional ownership trends for DexCom.

Which institutional investors are selling DexCom stock?

DXCM stock was sold by a variety of institutional investors in the last quarter, including IFM Investors Pty Ltd, and Acorn Financial Advisory Services Inc. ADV. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman, and Steven Robert Pacelli. View insider buying and selling activity for DexCom.

Which institutional investors are buying DexCom stock?

DXCM stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, DNB Asset Management AS, Louisiana State Employees Retirement System, NuWave Investment Management LLC, HNP Capital LLC, Paragon Advisors LLC, Polaris Greystone Financial Group LLC, and Diversified Trust Co. View insider buying and selling activity for DexCom.

How do I buy shares of DexCom?

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is DexCom's stock price today?

One share of DXCM stock can currently be purchased for approximately $404.23.

How big of a company is DexCom?

DexCom has a market capitalization of $37.33 billion and generates $1.48 billion in revenue each year. The medical device company earns $101.10 million in net income (profit) each year or $1.84 on an earnings per share basis. DexCom employs 3,900 workers across the globe.

What is DexCom's official website?

The official website for DexCom is www.dexcom.com.

How can I contact DexCom?

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.